When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind. Although it is ...

It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry. The key reason is simple: Drug ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

Both partners have the right to advance new targets discovered under the deal, with reciprocal success milestones and ...

A few years ago, West Virginia, which has the highest obesity rate in the nation, quietly began a small and unusual pilot ...

The WisdomTree U.S. Quality Dividend Growth Index underwent its annual rebalance on December 11, 2024, refining its holdings ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

Obesity has emerged as one of the most pressing public health challenges globally, affecting over 650 million adults, ...

Mike Plante struggled with his weight for years, but within six months of starting with the injection drug semaglutide, a ...

If you are considering a natural over the counter Mounjaro alternative for 2025 - we have the top 3 options for you. SAN FRANCISCO, CA / ACCESSWIRE / December 18, 2024 / If you've been following ...

Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company.